IDEC 132 oral

Drug Profile

IDEC 132 oral

Alternative Names: 9-AC PEG-1000 - IDEC; 9-aminocamptothecin PEG-1000 - IDEC; IDEC 132 colloidal dispersion; IDEC 132 PEG-1000; PEG-1000 - IDEC

Latest Information Update: 10 Aug 1999

Price : $50

At a glance

  • Originator IDEC Pharmaceuticals
  • Class Alkaloids; Camptothecins; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 10 Aug 1999 Discontinued-II for Cancer in USA (PO)
  • 09 Aug 1999 Clinical studies have been added to the pharmacokinetics section
  • 28 Jul 1999 Phase-I clinical trials for Solid tumours in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top